Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System

Overview
This study ran CD3+ T cells from healthy-donor leukapheresis through the Quantum Cell Expansion System, a closed automated hollow-fiber bioreactor, for 8-9 days. Two seeding densities, 30 and 85 × 10^6 cells, gave means of 14.8 and 25.1 × 10^9 cells at harvest, with viability at or above 90%.
What this paper found
The Quantum Cell Expansion System, a closed automated hollow-fiber bioreactor, expanded CD3+ T cells from healthy-donor leukapheresis products to clinically relevant numbers in 8 to 9 days. Mononuclear cells from five donors were activated with anti-CD3/CD28 Dynabeads and cultured in xeno-free, serum-free medium with 100 IU/mL IL-2. Seeding 30 × 10^6 cells gave a mean of 14.8 × 10^9 cells, and seeding 85 × 10^6 gave 25.1 × 10^9 cells, with viabilities of 90% or higher. Mean CD3+ fold expansion was 1311 and 762, respectively, and doubling times were close to 20 hours. Harvested cells secreted IFN-γ, IL-2 and TNF-α after restimulation, had naïve and central memory phenotypes, and showed low LAG-3 and PD-1 expression.
Note: The study used non-gene-modified T cells from healthy donors; the authors note that evaluation with gene-modified T cells is a future direction.
The Quantum system has been successfully used to produce large quantities of functional T-cells at clinical dosing scale and within a short timeframe. — Claire Coeshott, Boah Vang, Mark Jones, Brian Nankervis, Journal of Translational Medicine
Study details
- Authors
- Claire Coeshott, Boah Vang, Mark Jones, Brian Nankervis
- Institution
- Terumo BCT, Inc., Lakewood, Colorado, USA
- Journal
- Journal of Translational Medicine
- Year
- 2019
- Cell type(s)
- T-Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
Full citation
Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System. J Transl Med. 2019;17(1):258.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.